#### Onset, duration, and persistence of taste and smell changes 1

2	and other	COVID-19 s	ymptoms:	<b>longitudinal</b>	study in	Israel
---	-----------	------------	----------	---------------------	----------	--------

patients 3

4

7

- Hadar Klein<sup>1</sup>#, Kim Asseo<sup>1</sup>#, Noam Karni<sup>2</sup>#, Yuval Benjamini<sup>3</sup>, Ran Nir-Paz<sup>4</sup>, Mordechai 5
- Muszkat<sup>2</sup>, Sarah Israel<sup>2§</sup>, Masha Y. Niv<sup>1§</sup>\* 6
- #equal contributions as first authors 8
- 9 §equal contributions as senior authors
- 10 \*corresponding author
- 11 <sup>1</sup>The Institute of Biochemistry, Food and Nutrition, The Hebrew University, Rehovot, Israel
- 12 <sup>2</sup>Department of Medicine, Hadassah University Hospital, Mt. Scopus Campus, Jerusalem, Israel
- 13 <sup>3</sup>Department of Statistics, The Hebrew University, Mt. Scopus Campus, Jerusalem, Israel
- 14 <sup>4</sup>Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University medical
- 15 center

16

20

- **KEYWORDS:** 17
- 18 COVID-19; smell change; taste change; symptoms duration; disease course; recovery;
- 19 symptoms persistence
- 21 **CORRESPONDING AUTHOR:**
- 22 Prof. Masha Y Niv, PhD
- 23 Chemical Senses and Molecular Recognition Lab

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 24 Robert H. Smith Faculty of Agriculture, Food and Environment, Rehovot, Israel
- 25 The Hebrew University of Jerusalem, Israel

E-mail: masha.niv@mail.huji.ac.il, Tel: +972-89489664 26

**ABSTRACT** 

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

**Objectives:** The multifaceted disease manifestation of COVID-19 requires longitudinal characterization of symptoms, to aid with screening and disease management. Methods: Phone interviews and follow-ups were completed with 112 mild COVID-19 RT-PCR-positive adult patients, over a six weeks period. Results: More than one symptom at disease onset was experienced by ~70 of the patients. Over one third of the patients experienced fever, dry cough, headache, or muscle ache as the first symptom. If fatigue was reported, it was usually the first symptom to appear. Smell and taste changes had occurred  $3.9 \pm 5.4$  and  $4.6 \pm 5.7$  days (mean ± SD) since disease onset and emerged as first symptoms in 15% and 18% of patients, respectively. Fever was the shortest lasting symptom (5.8 ± 8.6 days (mean ± SD), and smell and taste changes were the longest-lasting symptoms (24.3 ± 22.9 days and 19.4 ± 19.1 (mean ± SD), respectively), with longer smell recovery correlated with smell change severity. In one third of patients who reported cough, smell and taste changes, these symptoms persisted after negative RT-PCR tests. **Conclusions:** Each symptom can occur as first or later, some are more likely to appear as firsts, and typically more than one symptom occurs at disease onset. The severity of olfactory change is associated with its recovery time. Lack of chemosensory recuperation in recovered patients is common. These findings can aid patients through

their illness and provide expected recovery patterns.

### **BACKGROUND**

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

The coronavirus disease (COVID-19) has become a global pandemic, with more than 31 million globally reported cases as of September 24<sup>th</sup>, 2020 including 972,221 deaths (World Health Organization, 2020). This pandemic resulted in multiple socio-economic implications on a worldwide scale[1]. COVID-19 symptoms and severity vary widely[2,3]. It has been established that COVID-19 can result in prolonged illness even among milder patients[4]. Symptoms may persist post patient recovery, which is usually defined as symptoms improvement along with negative real time polymerase chain reaction (RT-PCR) test results for COVID-19[5]. COVID-19 initially targets the human respiratory system, with the most common symptoms according to the Centers for Disease Control and Prevention (CDC) being fever, cough, shortness of breath, fatigue, muscle aches, headache, new loss of smell or taste, sore throat, congestion, nausea/vomiting and diarrhea. Other commonly reported symptoms also include sputum production, hemoptysis and lack of appetite[6,7]. These symptoms' order of appearance, severity, durations and persistence after recovery, is only partly studied[5,8,9]. In this study, we address gaps in knowledge regarding the order of symptoms appearance and their durations in RT-PCR positive patients. Establishing COVID-19 course of illness in terms of symptoms severity, order of appearance, duration, and persistence after recovery, is of key importance for patients' ability to cope with the mental, social, and financial challenges that accompany the disease.

### **METHODS**

Aim and setting

This is a follow-up study of patients that participated in our previous study, see Karni and Klein et al.[10], performed in Israel, from April 2020 to May 2020. The study comprised of Israeli residents aged ≥18 years with positive COVID-19 RT-PCR results, who were recruited via social media (Twitter and Facebook) and word of mouth for phone interviews. We excluded severely ill patients, and non-Israeli residents. Participants were not screened or targeted for experiencing chemosensory changes. Informed consent was obtained from all participants. The study was approved by the Hadassah Medical Center Helsinki Committee (permit number 0236-20-HMO). Upon agreement to participate, the explanation of the interview, including questions on taste and smell, were read to the participants.

## **General design**

The questionnaire was developed in parallel with the Global Consortium for Chemosensory Research, GCCR[11]. The questionnaire[10] had five parts: 1) General information (e.g., age, gender); 2) Medical history (e.g., medical conditions, chronic medications use); 3) Current illness (e.g., 23 physical signs and symptoms, RT-PCR swab test results and dates, subjective recovery feeling); 4 and 5) Smell and taste: Participants were instructed to rate their sense of smell/taste before, during and after their illness, on a scale from 1-10 (1 corresponding to "no sense of smell" and 10 to excellent sense of smell). Data was kept in Compusense Cloud on-line software (Compusense Inc., Guelph, ON, Canada).

Patients follow-up

Covid-19 positive patients from our previous Karni and Klein et al. study[10], were followed here to monitor the progress of their illness and recovery. Out of 144 RT-PCR-positive patients, 114 had answered the phone, of which two had missing information regarding rating of chemosensory symptoms, resulting in 112 patients answering the first questionnaire.

Recovered patients' category refers to those who received two consecutive negative RT-PCR test results. Patients who either did not recover from their symptoms in the first questionnaire, or did not get two consecutive negative RT-PCR results at the time of answering the first questionnaire, were contacted 3 weeks after the initial interview, for their 3-week follow-up (n=101). If they had not fully recovered at their first follow-up, they were contacted again 3 weeks after their second interview, for their 6-week follow-up (n=46).

### Data analysis

The participants were asked about 27 symptoms (see web-only Supplementary Figure S1). 7 of these occurred in more than 50% of the patients (Taste change, smell change, fever, dry cough, muscle aches, headache, lack of appetite) and were included in the final analysis. All these symptoms, except lack of appetite, are current official CDC symptoms. Additional 7 symptoms of the less prevalent (<50%) symptoms are the remaining official CDC symptoms (productive cough, shortness of breath, fatigue, sore throat, congestion, nausea/vomiting, and diarrhea), and were therefore also included in the final analysis. "Fatigue" was not explicitly included in the original questionnaire because it was not a known symptom at the time of its drafting, but was nevertheless

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

self-reported in 18% of patients under "any other symptoms" and was therefore included in the final analysis. Disease onset is defined as the first appearance of any of the COVID-19 symptoms described above. Persistent symptoms are defined as symptoms that progress post patient's recovery. Order of appearance and duration were calculated from the dates reported by the participants for each symptom. Severity of smell (taste) change was calculated as the delta between the reported ability to smell before the illness and its reported ability during the illness, rated on a 1-10 scale. Statistical analysis Analyses were conducted using the statistical software R (https://www.rproject.org/). Descriptive statistics are presented as the mean and standard deviation. Pearson correlation coefficient was used for testing of correlations. A level of P<0.05 was used to determine statistical significance. **RESULTS:** Patients' characteristics Completed questionnaires were obtained from 112 COVID-19 positive patients. The median age of the respondents was  $35 \pm 12$  years (mean  $\pm$  SD) and included (64%) men. 6 patients were classified as hospitalized (received respiratory support during

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

their hospitalization and / or were hospitalized in the intensive care unit) and the remaining 106 were classified as ambulatory patients. Order of symptoms' appearance Symptoms appearance were usually concomitant: The first and second symptoms to appear were accompanied by additional symptoms in 69% and 45% of the patients, respectively. Headache, fever, dry cough, and muscle aches were the first symptoms to appear in more than one third of the patients (Figure 1A). Smell and taste changes were the first symptoms to appear (either solely or along with other symptoms) in only 15% and 18% of patients, respectively. Fatigue was as a first symptom in majority of patients who reported it(Figure 1A). Headache, fever, dry cough, and muscle aches appeared 1.99  $\pm$  5, 1.79  $\pm$  4.64, 1.35  $\pm$ 3.44 and 2.09  $\pm$  5.07 days (mean  $\pm$  SD), respectively, after illness onset. Smell and taste changes appeared later, at  $3.94 \pm 5.45$  and  $4.58 \pm 5.72$  days (mean  $\pm$  SD), respectively, after illness onset (Figure 1B). Each of the 14 symptoms analyzed here could occur as first or co-first, with vomiting, breathing difficulty and diarrhea being the most spread out in the order in which they appear (see web-only Supplementary Figure S2). Indeed, vomiting and diarrhea appeared after the highest number of days since illness onset

 $(5.57 \pm 8.26 \text{ and } 5.85 \pm 9.97, \text{ respectively})$  (Figure 1B).

perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .




Figure 1. Symptoms order. A. Prevalence of patients for which symptoms appeared as  $1^{st}$  and  $\geq 2^{nd}$  symptoms. Symptoms that appeared as  $1^{st}$  in more the third of the patients are presented with dark background, lower prevalence is presented in light blue background. B. Y axis lists symptoms and X axis shows number of days since illness started. the mean  $\pm$  SD number of days for symptom onset is presented for each symptom. Coloring is according to prevalence, with darkest color indicating most prevalent symptoms.

#### Distribution of symptoms durations and persistence

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

Figure 2A depicts the durations of the most prevalent symptoms (>50%) among 112 COVID-19 patients. Fever, lack of appetite, headache and muscle ache had shorter durations than those of dry cough and changes of taste and smell. In this sample of patients, the most prolonged symptoms lasted up to 78 days. 36% of patients with smell change, 32% of patients with taste change, and 27% with dry or productive cough, still had these symptoms post recovery (defined as two consecutive negative RT-PCR-test results) (Figure 2A). Similar results were found also when recovery is defined as 13 days after symptoms onset, as currently accepted in Israel (see web-only Supplementary Figure S3). Smell and taste changes duration present bimodal distributions, with patients who experienced these symptoms as persistent, comprising the second peak (Figure 2A (6-7)). As seen in Figure 2B, persistent taste change was usually accompanied by persistent smell change in the same patient, and in some cases also accompanied by a persistent cough (either productive or dry). Persistent cough could persist also in patients without persistent chemosensory change.




Figure 2. Symptoms durations and persistence. A. (1-7) Duration pattern graphs are presented for each symptom and colored according to symptom's persistence post recovery. Y axis shows number of patients (n) and X axis shows duration of symptoms (days). Persistent symptoms are colored purple and symptoms that did not persist are colored pink. Number of patients and the mean ± SD duration (days) of symptoms is presented for each graph. B. Euler-diagram of the most persistent symptoms after recovery, persistent smell and taste changes are marked green and blue, respectively. Cough is marked in seashell color. The number of patients experiencing a symptom as persistent is marked in each circle.

#### **Chemosensory recovery patterns**

We quantified the level smell and taste recovery during 6 weeks of follow-ups. We found three groups of patients: The 1<sup>st</sup> group recovered already at the time of the initial interview (their taste and smell ability ratings shown on Figures 3A and 3D). The 2<sup>nd</sup> group of patients were not recovered during initial interview and had one follow-up interview. Figures 3B and 3E show three smell and taste ratings before their illness, at the worst state during their illness and at the time of their second interview. The last group of patients did not recover during the follow-up interview and had a second follow-up. Figures 3C and 3F present four ratings for smell and taste: the score before their illness, at the worst state during their illness, and at the time of second and third interviews. The results indicate full recovery in patients from group 1 and 2, and a slower and gradual recovery of the senses in the last group.





Figure 3. Smell and taste ratings over 6-weeks follow-ups. A-C. Smell scores of patients recovered at the initial (A), second (B), and third (C) interviews. D-F. Taste scores of patients recovered at the initial (D), second (E), and third (F) interviews. Y axis shows rating of smell/taste ability and X axis depicts 5 time points ratings: before, during and after their illness, rated at initial questionnaire (blue), and at two following questionnaires (3-weeks (light blue) and 6-weeks (turquoise) follow-ups).

#### Smell change severity and recovery

We found that the durations of smell and taste were correlated (0.82, p<0.001) (Figure 4A), with many patients reporting identical durations for these symptoms.

As seen in Figure 4B, a small yet significant correlation was found also between smell change severity and its duration (correlation 0.34, p=0.003). The same was not repeated for taste change severity and its duration (see web-only Supplementary Figure S4).

Moreover, it is apparent that some patients' smell change had recovered independently of how severe it was, while for another group of patients, it was closely dependent on its severity (Figure 4B). We did not find any particular characteristics for either of these subgroups.



**Figure 4. Correlations of smell and taste change characteristics. A.** Correlation of smell and taste change durations (n=67). X axis shows smell change duration and Y axis shows taste change duration (days). **B.** Correlations between smell change severity and its duration (n=76). X axis shows smell change severity and Y axis shows smell change duration (days).

DISCUSSION

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

Smell and taste changes had emerged as distinctive COVID-19 symptoms[10,12]. Considering the importance of chemosensory disorders in COVID-19, it is essential to further study these symptoms in terms of order of appearance in relation to other COVID-19 symptoms, duration, and persistence post recovery. Spinato et al.[13] had found that the time of onset of smell or taste changes was prior to other symptoms in 11.9% of cases and concomitant with other symptoms in 22.8% of cases. In terms of symptoms durations, different reports found that the time for chemosensory recovery is ranging from 8.02 ± 6.41 to 11.6 ± 6.2 days (mean ± SD)[14,15], others found their persistence post recovery in the range of 20% to 78% of patients[5,16]. Our study reveals that smell and taste were the first symptoms to appear, in 15% and 18% of cases, respectively, either with or without other symptoms. We found duration of smell change to be 24.3 ± 22.9 days and of taste change to be 19.4 ± 19.1 days (mean ± SD), and their post-recovery persistence to be prevalent in 36% and 32% of patients, respectively. Concerning other COVID-19 symptoms, we found that even though their order of appearance is varied, headache, fever, dry cough, and muscle aches were often (38% -43%) the first symptoms to appear. Additionally, out of the 18% patients who experienced fatigue, 80% had experienced it as a first symptom (14% of all patients). Of note, the prevalence of fatigue in our study was lower than previously reported 36%-46%[17,18], probably because here it was not explicitly part of the questionnaire, but rather self-reported under the "any other symptom" question.

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

Furthermore, we found COVID-19 illness to have a prolonged phase, in which symptoms such as fever, lack of appetite, headache and muscle aches are recovered, but dry cough, taste change and smell change persist, with the latter having the longest duration of 24.3 ± 22.9 days (mean ± SD). The prolonged phase can persist post-recovery: chemosensory changes were found to persist post recovery in about one third of patients experiencing them (usually by the same patient). Additionally, cough, either dry or productive, was also found to persist in approximately 27% of patients who reported experiencing this symptom. However, patients experiencing cough as persistent can be the same or different than those experiencing persistent chemosensory changes. We found slightly lower prevalence of patients who experienced chemosensory changes as first symptoms than those previously reported[13], which could be due to recall bias caused by retrospective data collection. We also report a lower percentage of persistence post recovery prevalence of smell and taste changes compared to another study [16], which could be sue to our larger sample size or other differences. Longer duration of chemosensory changes that those reported by others[14,15,19] is due to the longer follow-ups we conducted. Moreover, our detailed phone interviews did not rely on online surveys, increasing the reliability of the data. Importantly, some surveys did not use scales to determine smell and taste changes and recovery, but rather counted them as binary symptoms[19]. Here we monitored quantitative recovery back to normal levels, possibly accounting for the longer recovery rate we found for the chemosensory changes and higher persistence postrecovery than when binary classification was used[5].

We found smell (but not taste) change severity to be correlated with its time to recover. However, while for a group of the patients, the time necessary for their smell change recovery correlated with magnitude of the change they had experienced, for another group, the severity of their smell change was unrelated to the time it took to recover. Such grouping was also reported by Gerkin et al.[12], but characteristics that might account for the differences between these two groups could not yet be unraveled and require future study.

#### **Study limitations**

Our sample did not include severely ill patients, and therefore is relevant for light to moderately ill patients only. No objective testing was performed, and the information was self-reported by the participants. Additionally, the retrospective data collection method used in this study may have caused recall bias.

Our study focuses on a relatively short period (6 weeks) of post-acute illness stage, and future studies of large groups of long lasting and persistent symptoms of COVID-19 during longer periods of time are likely to reveal additional manifestations of "long COVID" [20].

### **Conclusions**

We have carefully mapped the start and end dates of various COVID-19 symptoms of 112 mild patients in Israel. The results indicate that despite large variability in symptoms onset and duration, some symptoms (headache, fever, dry cough, and muscle aches) are common as first or co-first symptoms. Fatigue, if occurs, usually appears as first. Taste and smell changes are not typically first, and appear on average,

 $3.9 \pm 5.4$  and  $4.6 \pm 5.7$  days (mean  $\pm$  SD), respectively, since illness onset. Their recovery can be either fast, or longer and gradual, sometimes accompanied by cough. Interestingly, while dry cough appears early  $(1.35 \pm 3.44 \text{ days (mean } \pm \text{SD)})$  and productive cough later  $(4.54 \pm 7.09 \text{ days (mean } \pm \text{SD)})$ , both types of cough may persist post recovery. This information regarding their symptoms' durations and persistence post recovery, can potentially reduce anxiety and promote better management of patients financial, social, and mental wellbeing during the disease.

### **Authors' contributions**

NK and MYN initiated the research, SI, NK and MM wrote the IRB proposal, NK recruited patients, NK, MYN, YB, SI and MM designed the research, SI, MM, RNP and MYN supervised the research, HK carried out the interviews, HK and MYN drafted the manuscript, KA and YB preformed the statistical analysis, KA and HK created figures and tables. All authors contributed to writing and approved the final manuscript.

# References

322

323	[1]	Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the
324		coronavirus pandemic (COVID-19): A review. Int J Surg. 2020;78:185-193.
325		doi:10.1016/j.ijsu.2020.04.018
326	[2]	Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease
327		2019 in China. N Engl J Med. 2020;382(18):1708-1720.
328		doi:10.1056/NEJMoa2002032
329	[3]	Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the Clinical
330		Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med.
331		2020;35(5):1545-1549. doi:10.1007/s11606-020-05762-w
332	[4]	Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors
333		for Delayed Return to Usual Health Among Outpatients with COVID-19 in a
334		Multistate Health Care Systems Network - United States, March-June
335		2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993-998. Published 2020
336		Jul 31. doi:10.15585/mmwr.mm6930e1
337	[5]	Carfi A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study
338		Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA.
339		2020;324(6):603-605. doi:10.1001/jama.2020.12603
340	[6]	Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus
341		disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
342		doi:10.1016/j.jaut.2020.102433
343	[7]	Pan L, Mu M, Yang P, et al. Clinical Characteristics of COVID-19 Patients With
344		Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional,
345		Multicenter Study. Am J Gastroenterol. 2020;115(5):766-773.

346		doi:10.14309/ajg.000000000000000000000000000000000000
347	[8]	Larsen JR, Martin MR, Martin JD, Kuhn P, Hicks JB. Modeling the Onset of
348		Symptoms of COVID-19. Front Public Health. 2020;8:473. Published 2020 Aug
349		13. doi:10.3389/fpubh.2020.00473
350	[9]	Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat
351		AR. Olfactory Dysfunction and Sinonasal Symptomatology in COVID-19:
352		Prevalence, Severity, Timing, and Associated Characteristics. Otolaryngol Head
353		Neck Surg. 2020;163(1):114-120. doi:10.1177/0194599820929185
354	[10]	Karni N, Klein H, Asseo K, et al. Self-rated smell ability enables highly specific
355		predictors of COVID-19 status: a case control study in Israel. Preprint.
356		medRxiv. 2020;2020.07.30.20164327. Published 2020 Aug 01.
357		doi:10.1101/2020.07.30.20164327
358	[11]	Parma V, Ohla K, Veldhuizen MG, et al. More than smell - COVID-19 is
359		associated with severe impairment of smell, taste, and chemesthesis
360		[published online ahead of print, 2020 Jun 20]. Chem Senses. 2020;bjaa041.
361		doi:10.1093/chemse/bjaa041
362	[12]	Gerkin RC, Ohla K, Veldhuizen MG, et al. Recent smell loss is the best predictor
363		of COVID-19: a preregistered, cross-sectional study. Preprint. medRxiv.
364		2020;2020.07.22.20157263. Published 2020 Jul 26.
365		doi:10.1101/2020.07.22.20157263
366	[13]	Spinato G, Fabbris C, Polesel J, et al. Alterations in Smell or Taste in Mildly
367		Symptomatic Outpatients With SARS-CoV-2 Infection. JAMA.
368		2020;323(20):2089-2090. doi:10.1001/jama.2020.6771
	[14]	Sakalli E, Temirbekov D, Bayri E, Alis EE, Erdurak SC, Bayraktaroglu M. Ear nose

throat-related symptoms with a focus on loss of smell and/or taste in COVID-370 371 19 patients [published online ahead of print, 2020 Jun 23]. Am J Otolaryngol. 2020;41(6):102622. doi:10.1016/j.amjoto.2020.102622 372 Gorzkowski V, Bevilacqua S, Charmillon A, et al. Evolution of Olfactory 373 [15] Disorders in COVID-19 Patients [published online ahead of print, 2020 Jul 374 2]. Laryngoscope. 2020;10.1002/lary.28957. doi:10.1002/lary.28957 375 Yan CH, Prajapati DP, Ritter ML, DeConde AS. Persistent Smell Loss Following 376 [16] 377 Undetectable SARS-CoV-2 [published online ahead of print, 2020 Jun 9]. Otolaryngol Head Neck Surg. 2020;194599820934769. 378 379 doi:10.1177/0194599820934769 [17] Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, 380 discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577-381 382 583. doi:10.1002/jmv.25757 383 [18] Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis [published online ahead of print, 2020 Apr 15]. J Med Virol. 384 2020;10.1002/jmv.25884. doi:10.1002/jmv.25884 385 Lee Y, Min P, Lee S, Kim SW. Prevalence and Duration of Acute Loss of Smell or 386 [19] Taste in COVID-19 Patients. J Korean Med Sci. 2020;35(18):e174. Published 387 2020 May 11. doi:10.3346/jkms.2020.35.e174 388 Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-389 [20] acute covid-19 in primary care. BMJ. 2020;370:m3026. Published 2020 Aug 11. 390 doi:10.1136/bmj.m3026 391 392

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

LIST OF ABBREVIATIONS CDC - Centers for Disease Control and Prevention SARS-CoV-2 - Severe Acute Respiratory Syndrome Coronavirus 2 SD - Standard Deviation GCCR - Global Consortium for Chemosensory Research RT-PCR – Real Time Polymerase Chain Reaction **URI** -Upper Respiratory tract Infections **Ethics approval** The study was conducted in accordance with Helsinki committee and the required ethics approval was granted (reference number HMO-0236-20). Ethics, consent, and permissions Written informed consents for publication of patients' clinical details were obtained from the patients TRANSPARECY DECLARATION **Competing interests** The authors declare that they have no competing interests. Funding MYN is supported by Israel Science Foundation (ISF) grant #1129/19. HK is a recipient of the Uri Zehavi Scholarship.

**Acknowledgements** 

417

421

- 418 We thank the Global Consortium for Chemosensory Research (GCCR) team for
- 419 inspiring the questionnaire used in this research. We thank Yehuda Tarnovsky for help
- with patient's recruitment.